SPRO vs. AGLE, TTPH, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, ADCT, and VNDA
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Aeglea BioTherapeutics (AGLE), Tetraphase Pharmaceuticals (TTPH), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), ADC Therapeutics (ADCT), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "medical" sector.
Aeglea BioTherapeutics (NASDAQ:AGLE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
Aeglea BioTherapeutics has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.
Spero Therapeutics has higher revenue and earnings than Aeglea BioTherapeutics. Aeglea BioTherapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Spero Therapeutics had 2 more articles in the media than Aeglea BioTherapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for Aeglea BioTherapeutics. Aeglea BioTherapeutics' average media sentiment score of 1.60 beat Spero Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media.
Aeglea BioTherapeutics presently has a consensus price target of $17.50, indicating a potential upside of ∞. Spero Therapeutics has a consensus price target of $7.00, indicating a potential upside of 392.96%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Aeglea BioTherapeutics is more favorable than Spero Therapeutics.
25.6% of Spero Therapeutics shares are owned by institutional investors. 6.6% of Aeglea BioTherapeutics shares are owned by company insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aeglea BioTherapeutics received 53 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.31% of users gave Spero Therapeutics an outperform vote while only 56.70% of users gave Aeglea BioTherapeutics an outperform vote.
Spero Therapeutics has a net margin of 21.09% compared to Spero Therapeutics' net margin of -22,195.36%. Aeglea BioTherapeutics' return on equity of 35.42% beat Spero Therapeutics' return on equity.
Summary
Spero Therapeutics beats Aeglea BioTherapeutics on 13 of the 17 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
